Sulfonamide Injectable Formulation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current sulfonamide injection formulations experience low stability and tend to crystallize due to suberic acid and p-toluenesulfonic acid, causing irritation at the injection site and reducing efficacy.
Innovation Solution
The formulation is improved by replacing suberic acid with sebacic acid and p-toluenesulfonic acid with 2-ethyl-1,3-hexanediol, combined with PEG-400, 1,2-propanediol, dimethyl sulfoxide, and anhydrous ethanol, to enhance solubility and stability, and reduce irritation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If suberic acid and p-toluenesulfonic acid are used in the formulation, then solubility of sulfonamide compounds is improved, but stability decreases and crystallization occurs after long storage
Solution Approach 1:
The patent changes the chemical parameters by replacing suberic acid with sebacic acid and p-toluenesulfonic acid with 2-ethyl-1,3-hexanediol. This substitution maintains the solubility-enhancing function while eliminating the instability and crystallization problems associated with the original acids.
Solution Approach 2:
The patent replaces the problematic acid components with alternative substances that achieve the same solubility function without the long-term stability issues, effectively using substitute materials that don't suffer from the same degradation pathways.
2Quantity of substance
If suberic acid and p-toluenesulfonic acid are used in the formulation, then solubility is improved, but irritation to the injection site increases
Solution Approach 1:
The patent changes the chemical nature of the formulation by substituting the irritating acids with sebacic acid and 2-ethyl-1,3-hexanediol, which maintain solubility while reducing the harmful irritation effect at the injection site.
Solution Approach 2:
The patent introduces 2-ethyl-1,3-hexanediol as an intermediary substance that facilitates solubility without causing irritation, acting as a mediator between the sulfonamide compound and the biological system.
3Ease of manufacture
If suberic acid and p-toluenesulfonic acid are used in the formulation, then preparation is simplified, but toxicity increases
Solution Approach 1:
The patent modifies the chemical composition parameters by replacing toxic acids with less toxic alternatives (sebacic acid and 2-ethyl-1,3-hexanediol) that maintain ease of preparation while significantly reducing the toxic burden on patients.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new formulation significantly increases stability, reduces toxicity, and maintains efficacy with improved solubility and reduced irritation, as demonstrated by comparative studies and clinical trials.
Implementation Method 1
The formulation is improved by replacing suberic acid with sebacic acid and p-toluenesulfonic acid with 2-ethyl-1,3-hexanediol, combined with PEG-400, 1,2-propanediol, dimethyl sulfoxide, and anhydrous ethanol, to enhance solubility and stability
Implementation Method 2
The above formulation has low stability, tends to crystallize after long storage time... This invention effectively solved the problems by replacing suberic acid with sebacic acid, and replacing p-toluenesulfonic acid with 2-ethyl-1,3-hexanediol
Data Source
AI summary
A sulfonamide pharmaceutical composition. The present invention relates to a sulfonamide compound injectable preparation comprising a sulfonamide compound or a derivative thereof. The injectable preparation is prepared from the sulfonamide compound and a pharmaceutically acceptable carrier through certain preparation technologies. The sulfonamide compound injectable preparation involved in the present invention is stable and controllable in quality and effective.